New York is currently home to 4473 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Recruiting
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis Fungoides
Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Recruiting
This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
Recruiting
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once week... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
03/10/2025
Locations: Kings Country Hospital Center, Brooklyn, New York
Conditions: HSV Infection
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism. The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/10/2025
Locations: Northwell Health System, Manhasset, New York
Conditions: Venous Thromboembolism
Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry
Recruiting
Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
03/10/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
03/09/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
Recruiting
Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities for early AF detection and subsequent stroke prevention in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long term arrhythmia information via remote monitoring. The ASSERT-AF study seeks to accurately define the burden of AF and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Heart Failure
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
Recruiting
APEX is a prospective multi-site registry of real-world experience with the Optilume™ BPH Catheter System for treatment of men experiencing symptomatic BPH.
Gender:
MALE
Ages:
All
Trial Updated:
03/07/2025
Locations: Northwell Health - Smith Institute of Urology, Syosset, New York
Conditions: Benign Prostatic Hyperplasia
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
Recruiting
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: NYU Langone Comprehensive Epilepsy Center, New York, New York
Conditions: Focal Onset Seizures
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Recruiting
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participa... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
03/07/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Testosterone and Neural Function
Recruiting
Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations,... Read More
Gender:
MALE
Ages:
Between 18 years and 80 years
Trial Updated:
03/07/2025
Locations: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York
Conditions: Spinal Cord Injury
LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF
Recruiting
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/07/2025
Locations: Tenax Investigational Site, New York, New York
Conditions: Pulmonary Hypertension